Style | Citing Format |
---|---|
MLA | Salimijeda A, et al.. "Sars-Cov-2: Current Trends in Emerging Variants, Pathogenesis, Immune Responses, Potential Therapeutic, and Vaccine Development Strategies." International Immunopharmacology, vol. 101, no. , 2021, pp. -. |
APA | Salimijeda A, Abbassi S, Mousavizadeh A, Esghaie M, Bokharaeisalim F, Jeddi F, Shafaati M, Abdoli A (2021). Sars-Cov-2: Current Trends in Emerging Variants, Pathogenesis, Immune Responses, Potential Therapeutic, and Vaccine Development Strategies. International Immunopharmacology, 101(), -. |
Chicago | Salimijeda A, Abbassi S, Mousavizadeh A, Esghaie M, Bokharaeisalim F, Jeddi F, Shafaati M, Abdoli A. "Sars-Cov-2: Current Trends in Emerging Variants, Pathogenesis, Immune Responses, Potential Therapeutic, and Vaccine Development Strategies." International Immunopharmacology 101, no. (2021): -. |
Harvard | Salimijeda A et al. (2021) 'Sars-Cov-2: Current Trends in Emerging Variants, Pathogenesis, Immune Responses, Potential Therapeutic, and Vaccine Development Strategies', International Immunopharmacology, 101(), pp. -. |
Vancouver | Salimijeda A, Abbassi S, Mousavizadeh A, Esghaie M, Bokharaeisalim F, Jeddi F, et al.. Sars-Cov-2: Current Trends in Emerging Variants, Pathogenesis, Immune Responses, Potential Therapeutic, and Vaccine Development Strategies. International Immunopharmacology. 2021;101():-. |
BibTex | @article{ author = {Salimijeda A and Abbassi S and Mousavizadeh A and Esghaie M and Bokharaeisalim F and Jeddi F and Shafaati M and Abdoli A}, title = {Sars-Cov-2: Current Trends in Emerging Variants, Pathogenesis, Immune Responses, Potential Therapeutic, and Vaccine Development Strategies}, journal = {International Immunopharmacology}, volume = {101}, number = {}, pages = {-}, year = {2021} } |
RIS | TY - JOUR AU - Salimijeda A AU - Abbassi S AU - Mousavizadeh A AU - Esghaie M AU - Bokharaeisalim F AU - Jeddi F AU - Shafaati M AU - Abdoli A TI - Sars-Cov-2: Current Trends in Emerging Variants, Pathogenesis, Immune Responses, Potential Therapeutic, and Vaccine Development Strategies JO - International Immunopharmacology VL - 101 IS - SP - EP - PY - 2021 ER - |